Sub-antidepressant Doses Suppress NLRP3 Inflammasome via P2X7 Receptor Blockade
🧪 Overview
Trazodone acts as a weak antagonist at P2X7 purinergic receptors (IC50 ~3 micromolar), suppressing microglial NLRP3 inflammasome activation at plasma concentrations achievable with 75-150 mg/day dosing. This reduces IL-1beta and IL-18 release in the brain parenchyma, interrupting the neuroinflammatory cycle that accelerates tau pathology spread. However, trazodone's IC50 of ~3 micromolar is at the edge of achievable brain concentrations, and human P2RX7 variants do not show genome-wide significant association with AD risk in large GWAS studies.
🧬 Mechanism
Curated pathway from expert analysis
flowchart TD
A["Trazodone 75-150mg/day<br/>P2X7 Weak Antagonist IC50~3uM"]
B["P2RX7 Purinergic Receptor<br/>Microglial Activation Sensor"]
C["Reduced Calcium Influx<br/>K+ Efflux Blockade"]
D["NLRP3 Inflammasome<br/>Assembly Inhibition"]
E["Reduced IL-1beta IL-18<br/>Release in Brain Parenchyma"]
F["Interrupted Neuroinflammatory<br/>Cascade"]
G["Neuroprotection<br/>Reduced AD Progression"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
style A fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
style B fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style D fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style G fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — P2RX7
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for P2RX7 (P2X7 receptor), NLRP3 inflammasome, IL-1beta from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for P2RX7 (P2X7 receptor), NLRP3 inflammasome, IL-1beta.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF cognitively normal elderly subjects (65-85 years) receive trazodone 75-150 mg/day for 7 days, THEN brain P2X7 receptor occupancy will be less than 25% as measured by [11C]JNJ-54175446 PET imaging. | Mean brain P2X7 receptor occupancy <25% at 2 hours post-dose on day 7, with individual values ranging from 5-30% | — no observation — | pending | 0.35 |
| IF 5xFAD mice receive chronic trazodone (10 mg/kg/day via osmotic minipump) for 12 weeks starting at 3 months of age, THEN hippocampal IL-1β concentration will be reduced by ≥50% compared to vehicle-t | Hippocampal IL-1β concentration reduced by 50-70% in trazodone-treated 5xFAD mice; NLRP3 caspase-1 activity reduced by ≥40% | — no observation — | pending | 0.45 |
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |